CN1150898C - 富马酸单烷基酯在制备微型片剂药物组合物中的应用 - Google Patents
富马酸单烷基酯在制备微型片剂药物组合物中的应用Info
- Publication number
- CN1150898C CN1150898C CNB988138344A CN98813834A CN1150898C CN 1150898 C CN1150898 C CN 1150898C CN B988138344 A CNB988138344 A CN B988138344A CN 98813834 A CN98813834 A CN 98813834A CN 1150898 C CN1150898 C CN 1150898C
- Authority
- CN
- China
- Prior art keywords
- fumaric acid
- application
- neurodermatitis
- pharmaceutical composition
- micro tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 11
- 201000009053 Neurodermatitis Diseases 0.000 title claims abstract description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 title claims abstract description 6
- -1 alkyl hydrogen Chemical compound 0.000 title abstract description 6
- 208000011231 Crohn disease Diseases 0.000 title abstract description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 title 1
- 239000001257 hydrogen Substances 0.000 title 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 45
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- 239000001530 fumaric acid Substances 0.000 claims description 21
- 239000006187 pill Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 12
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims description 10
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims description 10
- 125000005907 alkyl ester group Chemical group 0.000 claims description 8
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical class COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 5
- 208000004232 Enteritis Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 239000007916 tablet composition Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008188 pellet Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000002237 fumaric acid derivatives Chemical class 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 241000053227 Themus Species 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 125000004494 ethyl ester group Chemical class 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- BSSNZUFKXJJCBG-OWOJBTEDSA-N (e)-but-2-enediamide Chemical compound NC(=O)\C=C\C(N)=O BSSNZUFKXJJCBG-OWOJBTEDSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001606075 Ganyra josephina Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- YRPQEKFZVJEVNK-SFRQHTGFSA-L calcium;(e)-4-methoxy-4-oxobut-2-enoate Chemical compound [Ca+2].COC(=O)\C=C\C([O-])=O.COC(=O)\C=C\C([O-])=O YRPQEKFZVJEVNK-SFRQHTGFSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- BZCOSCNPHJNQBP-OWOJBTEDSA-N dihydroxyfumaric acid Chemical compound OC(=O)C(\O)=C(/O)C(O)=O BZCOSCNPHJNQBP-OWOJBTEDSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229910052500 inorganic mineral Chemical class 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Chemical class 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- IAQRGUVFOMOMEM-ONEGZZNKSA-N trans-but-2-ene Chemical compound C\C=C\C IAQRGUVFOMOMEM-ONEGZZNKSA-N 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
本发明涉及一种或多种以下通式的富马酸单烷基酯，其中R是C1-5烷基，任选地与以下式的二烷基富马酸酯以及任选的常规药物学上可接受的赋形剂和载体混合，在制备微型片剂或者微型丸剂形式的、用于治疗牛皮癣、牛皮癣性关节炎、神经性皮炎和节段性肠炎的药物组合物中的应用。
Description
技术领域
本发明涉及游离酸形式的某些富马酸单烷基酯在单独或者与富马酸二烷基酯组合时在制备微型片剂药物组合物中的应用，该药物组合物可用于治疗牛皮癣、牛皮癣性关节炎、神经性皮炎和Crohn节段性肠炎。
背景技术
给药后由于生物降解而进入柠檬酸循环或者属于该循环的药物制剂在通常高剂量时正逐渐取得更高的重要性，这是因为在它们的帮助下可以缓解或者治愈隐原性疾病。
因此，富马酸抑制鼠中Ehrlich腹水肿瘤的生长，降低丝裂霉素C和黄曲霉毒素的毒性(参考：K.Kuroda，M.Akao，Biochem.Pharmacol.29，2839-2844(1980)/Gann.72，777-782(1981)/Cancer Res.36，1900-1903(1976))，而且还具有抗牛皮癣和抗微生物作用(C.N.Huhtsnen，J.Food Sci.48，1574(1983)/M.N.Islam，US-A-4,346,118/C.A.97，161317b(1982))。
当通过非胃肠道、皮肤而且特别是经口给药时，高剂量的用于此目的的已知富马酸衍生物，如二羟基富马酸、富马酰胺和反式丁烯二腈，具有令人不可接受的副作用和高毒性(P.Holland，R.G.White，Brit.J.Dermatol.85，259-263(1971)/M.Hagedom，K.W.Kalkoff，G.Kiefer，D.Baron，J.Hug，J.Peteres，Arch.Derm.Res.254，67-73(1975))，使得该治疗通常不得不被放弃。
EP-A-0 188 749已描述了用于治疗牛皮癣的富马酸衍生物(盐)和包含该衍生物的药物组合物。
从DE-A-25 30 372中可知包含富马酸和其他富马酸衍生物之混合物的药物组合物，该组合物可用于治疗牛皮癣。富马酸的含量是强制性的。
DE-A-26 21 214描述了用于治疗牛皮癣的药物，该药物包含富马酸单乙基酯及其矿物盐作为活性成分。另外，EP-A-0 312 697描述了各种富马酸单烷基酯盐在治疗牛皮癣、牛皮癣性关节炎、神经性皮炎和Crohn节段性肠炎中的应用。
富马酸单乙基酯盐(Ca、Zn、Mg)和富马酸二甲基酯在治疗牛皮癣中的应用从出版物“Hautarzt”(1987，279-285)中是已知的。
因为在牛皮癣性表皮中，磷脂酶A2的活性被改变，富马酸刺激该酶的事实是对本发明组合物之机理的一个可能解释。
发明内容
令人惊奇的是，我们已经发现，用富马酸单烷基酯治疗牛皮癣，即使在没有形成盐的情况下，也可用包含游离酸形式的一种或多种C1-5富马酸单烷基酯的药物组合物来实现，该组合物还可任选地包含药物学上可接受的赋形剂和载体，而且该组合物为微型片剂或者微型丸剂。任选地，这些组合物也可包含一种或多种富马酸二烷基酯。
具体实施方式
微型片剂或者微型丸剂的组合物使得能够给药游离酸来代替盐，并且不发生已知的副作用、特别是形成溃疡。这有可能是因为以下事实：微型片剂或者微型丸剂使药物能够均匀地分散在胃中，由此避免了游离酸形式的单富马酸单烷基酯的局部刺激浓度。
包含20-300mg富马酸单烷基酯的组合物特别适合于口服给药，而活性成分的总重量为100-300mg。
对于开始全身治疗或者停止该治疗，包含100-120mg活性成分的低剂量，例如30.0-35.0mg的富马酸二甲基酯和70-90mg富马酸单甲基酯，是有利的。
190-210mg的活性成分，例如120.0mg的富马酸二甲基酯和90.0mg富马酸单乙基酯的形式，是初始阶段后的治疗剂量的一个例子。
根据本发明的组合物可以微型片剂或者经包胶的微型片剂或微型丸剂的形式经口给药，固体单个剂量药物剂型在几分钟内溶解在胃中，并由药物制剂中均匀地释放活性成分。低剂量对于开始或者停止全身给药是必须的，而初始阶段后对于治疗则需要更高的剂量。
根据本发明的微型片剂是用本领域已知的技术制造的，例如制粒、筛选、挤出/成球等。除活性成分外，它们还可包含常规的赋形剂和载体，如乳糖、PVP等。微型片剂或者微型丸剂的尺寸优选为300-2000μm，更优选为500-1500μm，并最优选为1000μm。
为便于给药单个剂量，微型片剂或者微型丸剂可进行包胶，例如包胶在明胶胶囊中。任选地，微型片剂或者微型丸剂可包覆耐胃酸的包衣。此等包衣可用已知方法包覆，例如在流化床装置中涂敷或者喷涂，或者是薄膜包衣。
实施例
制造包含50.0mg富马酸单甲基酯(相当于总共44.6mg的富马酸)并经
包胶的微型丸剂
采取必要的防范措施(呼吸面罩、手套、保护衣)，用#400筛网粉碎5000kg的富马酸单甲基酯，并均化。另外，制备2升的20％(m/v)聚乙烯吡咯烷酮(Kollidon K30)乙醇溶液。在包衣锅中引入7.250kg的Nonpareilles丸，并喷洒部分Kollidon K-30溶液直至略微湿润。然后加入部分活性成分混合物，直至丸剂干燥。继续进行该湿润/干燥步骤，直至加入所有的活性成分混合物。最后，在锅中摇动丸剂直至完全干燥。然后将丸剂填入硬明胶胶囊中(126.5mg丸剂/胶囊)。
发现对于各种临床形式的牛皮癣、牛皮癣性关节炎、神经性皮炎和Crohn节段性肠炎(Crohn病)，与包含已知成盐形式的富马酸衍生物的制剂相比，根据本发明的制剂具有类似的作用，但是没有给药游离酸时的已知副作用。
急性毒性的检查
在临床实验前，通过向鼠口服给药来检查富马酸单甲基酯的急性毒性。结果表明所用的富马酸具有非常低的毒性(见表1)。
表1：鼠中的急性毒性(口服给药)
| 性别 | 富马酸单甲基酯 | |
| LD50 | 雄性 | 2606.8 |
| 雌性 | 1777.8 | |
| 最低致死量(mg/kg) | 雄性 | 2150.0 |
| 雌性 | 1470.0 |
药物效力
分别比较Fumaderm forte(欧洲专利0 312 697 B1中的实施例4)和富马酸单甲基酯或者富马酸单乙基酯钙盐的药代动力学数据。
表2：效力
| 给药的物质 | 动物种类 | 剂量(mg/kg体重) | 富马酸单甲基酯浓度(Cmax)/(μg/ml) |
| Fumaderm forte | 鼠 | 30 | 8.99 |
| 富马酸单甲基酯 | 鼠 | 100 | 雄性：69.9雌性：84.5 |
| 富马酸单甲基酯钙盐 | 鼠 | 100 | 雄性：51.3雌性：107.0 |
Fumaderm forte：该混合物包含120mg的富马酸二甲基酯、87mg的富马酸单乙基酯钙盐、5mg的富马酸单乙基酯镁盐、3mg的富马酸单乙基酯锌盐。
Claims (5)
1、一种或多种以下通式的富马酸单烷基酯
其中R是C1-5烷基，任选地与以下式的二烷基富马酸酯
以及任选的常规药物学上可接受的赋形剂和载体混合，在制备微型片剂或者微型丸剂形式的、用于治疗牛皮癣、牛皮癣性关节炎、神经性皮炎和Crohn节段性肠炎的药物组合物中的应用，其中所述微型片剂或者微型丸剂的尺寸为300-2000μm。
2、如权利要求1所述的应用，其特征在于使用富马酸单甲基酯。
3、如权利要求1所述的应用，其特征在于使用富马酸单甲基酯和富马酸二甲基酯的混合物。
4、如权利要求1所述的应用，其是用于制备微型片剂或者微型丸剂形式的口服给药的药物组合物，其特征在于活性成分的总重量为20-300mg。
5、如权利要求1-4之一所述的应用，其是用于制备口服给药的药物组合物，其特征在于所述微型片剂或者微型丸剂具有肠溶包衣。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19814358.3 | 1998-03-31 | ||
| DE19814358A DE19814358C2 (de) | 1998-03-31 | 1998-03-31 | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1284870A CN1284870A (zh) | 2001-02-21 |
| CN1150898C true CN1150898C (zh) | 2004-05-26 |
Family
ID=7863089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB988138344A Expired - Fee Related CN1150898C (zh) | 1998-03-31 | 1998-12-08 | 富马酸单烷基酯在制备微型片剂药物组合物中的应用 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6277882B1 (zh) |
| EP (1) | EP1059920B1 (zh) |
| JP (1) | JP3527890B2 (zh) |
| CN (1) | CN1150898C (zh) |
| AT (1) | ATE219936T1 (zh) |
| AU (1) | AU745281B2 (zh) |
| BG (1) | BG64744B1 (zh) |
| BR (1) | BRPI9815772B8 (zh) |
| CA (1) | CA2283915C (zh) |
| CZ (1) | CZ291788B6 (zh) |
| DE (2) | DE19814358C2 (zh) |
| DK (1) | DK1059920T3 (zh) |
| EE (1) | EE04702B1 (zh) |
| ES (1) | ES2179551T3 (zh) |
| HK (1) | HK1035134A1 (zh) |
| HU (1) | HU228848B1 (zh) |
| IL (1) | IL136835A (zh) |
| NO (1) | NO327750B1 (zh) |
| NZ (1) | NZ505341A (zh) |
| PL (1) | PL191803B1 (zh) |
| PT (1) | PT1059920E (zh) |
| RS (1) | RS49658B (zh) |
| RU (1) | RU2197233C2 (zh) |
| SK (1) | SK285187B6 (zh) |
| TR (1) | TR200001829T2 (zh) |
| WO (1) | WO1999049858A1 (zh) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19839566C2 (de) * | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| RS52083B (sr) * | 2001-01-12 | 2012-06-30 | Fumapharm Ag | Amidi fumarne kiseline |
| DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| DE10217314A1 (de) * | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
| DE602004010531T2 (de) * | 2003-09-09 | 2008-07-03 | Fumapharm Ag | Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma |
| DE10360869A1 (de) * | 2003-09-09 | 2005-04-07 | Fumapharm Ag | Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma |
| PL2801355T3 (pl) | 2004-10-08 | 2015-10-30 | Fwp Ip Aps | Kompozycje farmaceutycznie o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego |
| US20080004344A1 (en) * | 2004-11-10 | 2008-01-03 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
| WO2007006307A2 (en) * | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| WO2007006308A1 (en) * | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use |
| EP1951206A1 (en) * | 2005-10-07 | 2008-08-06 | Aditech Pharma AB | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| EP1940382A2 (en) * | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| DK2139467T3 (da) * | 2007-02-08 | 2017-01-02 | Biogen Ma Inc | Neurobeskyttelse i demyelinisationssygdomme |
| DK2653873T3 (da) | 2007-02-08 | 2022-07-25 | Biogen Ma Inc | Sammensætninger og anvendelser til behandling af multipel sklerose |
| CA2730478C (en) | 2008-08-19 | 2014-04-15 | Xenoport, Inc. | Prodrugs of methyl hydrogen fumarate |
| ES2411972T5 (es) | 2009-01-09 | 2021-10-27 | Fwp Ip Aps | Formulación farmacéutica que comprende uno o más ésteres de ácido fumárico en una matriz de erosión |
| SI2718257T1 (en) | 2011-06-08 | 2018-04-30 | Biogen Ma Inc. | PROCEDURE FOR PREPARATION OF HIGH QUALITY CRYSTALINIC DIMETHY OF FUMARAT |
| RU2014125430A (ru) | 2011-11-24 | 2015-12-27 | Синтон Бв | Контролируемое высвобождение частиц, содержащих диметилфумарат |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| JP6189333B2 (ja) * | 2012-02-07 | 2017-08-30 | バイオジェン エムエー インコーポレーテッド | フマル酸ジメチルを含有する医薬組成物 |
| WO2013119791A1 (en) | 2012-02-07 | 2013-08-15 | Xenoport, Inc. | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
| KR101449114B1 (ko) * | 2012-08-21 | 2014-10-13 | 바이오스펙트럼 주식회사 | 푸마르산을 유효성분으로 포함하는 항염 조성물 |
| JP2015526477A (ja) * | 2012-08-22 | 2015-09-10 | ゼノポート，インコーポレイティド | メチル水素フマレートの経口剤形およびそのプロドラッグ |
| JP2015527372A (ja) * | 2012-08-22 | 2015-09-17 | ゼノポート，インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
| US20140171504A1 (en) | 2012-12-14 | 2014-06-19 | Georgia Regents Research Institute, Inc. | Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters |
| CN105142628A (zh) | 2012-12-21 | 2015-12-09 | 比奥根玛公司 | 氘取代的富马酸盐衍生物 |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| NZ723459A (en) | 2013-03-14 | 2017-12-22 | Alkermes Pharma Ireland Ltd | Prodrugs of fumarates and their use in treating various diseases |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| EP3038605A1 (en) | 2013-08-26 | 2016-07-06 | Forward Pharma A/S | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose |
| EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
| WO2015042294A1 (en) | 2013-09-18 | 2015-03-26 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
| JP6337135B2 (ja) | 2014-02-24 | 2018-06-06 | アルカーメス ファーマ アイルランド リミテッド | フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用 |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| US20170319548A1 (en) * | 2014-09-12 | 2017-11-09 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| WO2016061393A1 (en) | 2014-10-15 | 2016-04-21 | Xenoport, Inc. | Fumarate compounds, pharmaceutical compositions, and methods of use |
| KR102487136B1 (ko) | 2015-02-08 | 2023-01-10 | 엘커메스 파마 아일랜드 리미티드 | 모노메틸푸마레이트 전구약물 조성물 |
| DK3273951T3 (da) | 2015-03-27 | 2020-11-02 | Symbionyx Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til behandling af psoriasis |
| WO2017060420A1 (en) | 2015-10-07 | 2017-04-13 | Neurovive Pharmaceutical Ab | Protected fumaric acid-based metabolites for the treatment of autoimmune diseases |
| CN105496804A (zh) * | 2015-12-25 | 2016-04-20 | 知识产权全资有限公司 | 用于处理头发以及治疗头部牛皮藓的配方及其试剂盒和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2530372A1 (de) * | 1975-07-08 | 1977-01-13 | Walter Dr Schweckendiek | Pharmazeutische zubereitungen zur behandlung von psoriasis |
| DE2621214C3 (de) * | 1976-05-13 | 1981-11-12 | Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen | Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen |
| DE3127432A1 (de) * | 1981-07-11 | 1983-02-03 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von fumarsaeuremonoester |
| US5242905A (en) * | 1987-09-04 | 1993-09-07 | Dexter Chemical Corporation | Pharmaceutical compositions for the treatment of psoriasis |
| US5214196A (en) * | 1987-09-04 | 1993-05-25 | Dexter Chemical Corporation | Diethyl ester of di-glycyl fumaramide |
| US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| US5424332A (en) * | 1987-10-19 | 1995-06-13 | Speiser; Peter P. | Pharmaceutical composition and process for the production thereof |
| DE8714143U1 (zh) * | 1987-10-23 | 1988-03-24 | Werler Kunststoffwerke Gmbh & Co, 4760 Werl, De | |
| DE3834794A1 (de) * | 1988-10-12 | 1990-04-19 | F Schielein | Oral zu verabreichendes mittel zur behandlung von psoriasis |
| WO1992012952A1 (en) * | 1991-01-18 | 1992-08-06 | Dexter Chemical Corporation | Malic acid derivatives and compositions for the treatment of psoriasis |
| US5407772A (en) * | 1993-11-30 | 1995-04-18 | Xerox Corporation | Unsaturated polyesters |
| US5972363A (en) * | 1997-04-11 | 1999-10-26 | Rohm And Haas Company | Use of an encapsulated bioactive composition |
-
1998
- 1998-03-31 DE DE19814358A patent/DE19814358C2/de not_active Expired - Lifetime
- 1998-12-08 PL PL341240A patent/PL191803B1/pl unknown
- 1998-12-08 EE EEP200000440A patent/EE04702B1/xx not_active IP Right Cessation
- 1998-12-08 ES ES98965783T patent/ES2179551T3/es not_active Expired - Lifetime
- 1998-12-08 AU AU21593/99A patent/AU745281B2/en not_active Ceased
- 1998-12-08 CN CNB988138344A patent/CN1150898C/zh not_active Expired - Fee Related
- 1998-12-08 BR BRPI9815772 patent/BRPI9815772B8/pt unknown
- 1998-12-08 US US09/402,103 patent/US6277882B1/en not_active Expired - Lifetime
- 1998-12-08 HU HU0103234A patent/HU228848B1/hu not_active IP Right Cessation
- 1998-12-08 RU RU2000127112/14A patent/RU2197233C2/ru not_active IP Right Cessation
- 1998-12-08 AT AT98965783T patent/ATE219936T1/de active
- 1998-12-08 CZ CZ20003086A patent/CZ291788B6/cs not_active IP Right Cessation
- 1998-12-08 SK SK792-2000A patent/SK285187B6/sk not_active IP Right Cessation
- 1998-12-08 PT PT98965783T patent/PT1059920E/pt unknown
- 1998-12-08 CA CA002283915A patent/CA2283915C/en not_active Expired - Fee Related
- 1998-12-08 TR TR2000/01829T patent/TR200001829T2/xx unknown
- 1998-12-08 NZ NZ505341A patent/NZ505341A/en not_active IP Right Cessation
- 1998-12-08 DE DE59804704T patent/DE59804704D1/de not_active Expired - Lifetime
- 1998-12-08 EP EP98965783A patent/EP1059920B1/de not_active Expired - Lifetime
- 1998-12-08 WO PCT/EP1998/007956 patent/WO1999049858A1/de active IP Right Grant
- 1998-12-08 JP JP2000540824A patent/JP3527890B2/ja not_active Expired - Fee Related
- 1998-12-08 IL IL13683598A patent/IL136835A/xx not_active IP Right Cessation
- 1998-12-08 RS YUP-320/00A patent/RS49658B/sr unknown
- 1998-12-08 DK DK98965783T patent/DK1059920T3/da active
-
2000
- 2000-06-06 NO NO20002872A patent/NO327750B1/no not_active IP Right Cessation
- 2000-06-28 BG BG104566A patent/BG64744B1/bg unknown
-
2001
- 2001-08-13 HK HK01105619A patent/HK1035134A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1150898C (zh) | 富马酸单烷基酯在制备微型片剂药物组合物中的应用 | |
| RU2197963C2 (ru) | Применение производных фумаровой кислоты | |
| US4959389A (en) | Pharmaceutical preparation for the treatment of psoriatic arthritis | |
| US5424332A (en) | Pharmaceutical composition and process for the production thereof | |
| DE69731957T2 (de) | Orale pharmazeutische produkte mit peptiden | |
| US7803840B2 (en) | Utilization of dialkylfumarates | |
| CN1235578C (zh) | 富马酸微型片剂 | |
| CN1316901A (zh) | 富马酸衍生物在移植药物中的应用 | |
| DE19858789A1 (de) | Kombination von Cerivastatin und Fibraten | |
| CN1038903C (zh) | 喹嗜酮化合物或其盐在制备增强生长激素释放抑制因子或抑制该因子减少的药剂中的应用 | |
| MXPA00007089A (en) | Utilization of alkyl hydrogen fumerates for treating psoriasis, psoriatic arthritis, neurodermatitis and regional enteritis | |
| IL88011A (en) | Pharmacological preparations for the treatment of psoriasis, psoriatic arthritis, neurodermatitis and regionalitis entitis | |
| MXPA99010703A (en) | Use of fumaric acid derivatives | |
| JPH06305979A (ja) | 高脂血症予防、治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1035134 Country of ref document: HK |
|
| ASS | Succession or assignment of patent right |
Owner name: BIOLOGICAL GENE EDEK INTERNATIONAL CO., LTD. Free format text: FORMER OWNER: FUMAPHARM AG Effective date: 20130613 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Swiss Swiss Patentee after: Biogene Edke International Co.,Ltd. Address before: Swiss Swiss Patentee before: Biogene Edke International Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130613 Address after: Swiss Swiss Patentee after: Biogene Edke International Co.,Ltd. Address before: Luzern, Switzerland Patentee before: Fumapharm AG |
|
| C56 | Change in the name or address of the patentee |
Owner name: BIOGEN INTERNATIONAL GMBH Free format text: FORMER NAME: BIOLOGICAL GENE EDEK INTERNATIONAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Swiss Swiss Patentee after: Bio gene International Ltd. Address before: Swiss Swiss Patentee before: Biogene Edke International Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040526 Termination date: 20161208 |